Filtered By:
Source: Antimicrobial Agents and Chemotherapy
Infectious Disease: Gastroenteritis
This page shows you your search results in order of date.
Order by Relevance | Date
Total 445 results found since Jan 2013.
Dissemination of IncI plasmid encoding < em > bla < /em > < sub > CTX-M-1 < /sub > is not hampered by its fitness cost in the pig's gut
Antimicrob Agents Chemother. 2023 Sep 13:e0011123. doi: 10.1128/aac.00111-23. Online ahead of print.ABSTRACTMultiresistance plasmids belonging to the IncI incompatibility group have become one of the most pervasive plasmid types in extended-spectrum beta-lactamase-producing Escherichia coli of animal origin. The extent of the burden imposed on the bacterial cell by these plasmids seems to modulate the emergence of "epidemic" plasmids. However, in vivo data in the natural environment of the strains are scarce. Here, we investigated the cost of a blaCTX-M-1-IncI1 epidemic plasmid in a commensal E. coli animal strain, UB12-RC...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Margaux Allain Anne Claire Mah érault Benoit Gachet Caroline Martinez B énédicte Condamine M élanie Magnan Isabelle Kempf Erick Denamur Luce Landraud Source Type: research
Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing < em > Escherichia coli < /em >
Antimicrob Agents Chemother. 2023 Sep 13:e0051023. doi: 10.1128/aac.00510-23. Online ahead of print.ABSTRACTCefmetazole is active against extended-spectrum β-lactamase-producing Escherichia coli (ESBLEC) and is a potential candidate for carbapenem-sparing therapy. This multicenter, observational study included patients hospitalized for invasive urinary tract infection due to ESBLEC between March 2020 and November 2021 at 10 facilities in Japan, for whom either cefmetazole or meropenem was initiated as a definitive therapy within 96 h of culture collection and continued for at least 3 d. Outcomes included clinical and micr...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Kayoko Hayakawa Yasufumi Matsumura Kohei Uemura Shinya Tsuzuki Aki Sakurai Ryutaro Tanizaki Koh Shinohara Takehiro Hashimoto Ryota Hase Takashi Matono Hideaki Kato Momoko Mawatari Hiroshi Hara Yukihiro Hamada Sho Saito Norio Ohmagari Yohei Doi Source Type: research
Dissemination of IncI plasmid encoding < em > bla < /em > < sub > CTX-M-1 < /sub > is not hampered by its fitness cost in the pig's gut
Antimicrob Agents Chemother. 2023 Sep 13:e0011123. doi: 10.1128/aac.00111-23. Online ahead of print.ABSTRACTMultiresistance plasmids belonging to the IncI incompatibility group have become one of the most pervasive plasmid types in extended-spectrum beta-lactamase-producing Escherichia coli of animal origin. The extent of the burden imposed on the bacterial cell by these plasmids seems to modulate the emergence of "epidemic" plasmids. However, in vivo data in the natural environment of the strains are scarce. Here, we investigated the cost of a blaCTX-M-1-IncI1 epidemic plasmid in a commensal E. coli animal strain, UB12-RC...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Margaux Allain Anne Claire Mah érault Benoit Gachet Caroline Martinez B énédicte Condamine M élanie Magnan Isabelle Kempf Erick Denamur Luce Landraud Source Type: research
Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing < em > Escherichia coli < /em >
Antimicrob Agents Chemother. 2023 Sep 13:e0051023. doi: 10.1128/aac.00510-23. Online ahead of print.ABSTRACTCefmetazole is active against extended-spectrum β-lactamase-producing Escherichia coli (ESBLEC) and is a potential candidate for carbapenem-sparing therapy. This multicenter, observational study included patients hospitalized for invasive urinary tract infection due to ESBLEC between March 2020 and November 2021 at 10 facilities in Japan, for whom either cefmetazole or meropenem was initiated as a definitive therapy within 96 h of culture collection and continued for at least 3 d. Outcomes included clinical and micr...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Kayoko Hayakawa Yasufumi Matsumura Kohei Uemura Shinya Tsuzuki Aki Sakurai Ryutaro Tanizaki Koh Shinohara Takehiro Hashimoto Ryota Hase Takashi Matono Hideaki Kato Momoko Mawatari Hiroshi Hara Yukihiro Hamada Sho Saito Norio Ohmagari Yohei Doi Source Type: research
Dissemination of IncI plasmid encoding < em > bla < /em > < sub > CTX-M-1 < /sub > is not hampered by its fitness cost in the pig's gut
Antimicrob Agents Chemother. 2023 Sep 13:e0011123. doi: 10.1128/aac.00111-23. Online ahead of print.ABSTRACTMultiresistance plasmids belonging to the IncI incompatibility group have become one of the most pervasive plasmid types in extended-spectrum beta-lactamase-producing Escherichia coli of animal origin. The extent of the burden imposed on the bacterial cell by these plasmids seems to modulate the emergence of "epidemic" plasmids. However, in vivo data in the natural environment of the strains are scarce. Here, we investigated the cost of a blaCTX-M-1-IncI1 epidemic plasmid in a commensal E. coli animal strain, UB12-RC...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Margaux Allain Anne Claire Mah érault Benoit Gachet Caroline Martinez B énédicte Condamine M élanie Magnan Isabelle Kempf Erick Denamur Luce Landraud Source Type: research
Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing < em > Escherichia coli < /em >
Antimicrob Agents Chemother. 2023 Sep 13:e0051023. doi: 10.1128/aac.00510-23. Online ahead of print.ABSTRACTCefmetazole is active against extended-spectrum β-lactamase-producing Escherichia coli (ESBLEC) and is a potential candidate for carbapenem-sparing therapy. This multicenter, observational study included patients hospitalized for invasive urinary tract infection due to ESBLEC between March 2020 and November 2021 at 10 facilities in Japan, for whom either cefmetazole or meropenem was initiated as a definitive therapy within 96 h of culture collection and continued for at least 3 d. Outcomes included clinical and micr...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Kayoko Hayakawa Yasufumi Matsumura Kohei Uemura Shinya Tsuzuki Aki Sakurai Ryutaro Tanizaki Koh Shinohara Takehiro Hashimoto Ryota Hase Takashi Matono Hideaki Kato Momoko Mawatari Hiroshi Hara Yukihiro Hamada Sho Saito Norio Ohmagari Yohei Doi Source Type: research
Dissemination of IncI plasmid encoding < em > bla < /em > < sub > CTX-M-1 < /sub > is not hampered by its fitness cost in the pig's gut
Antimicrob Agents Chemother. 2023 Sep 13:e0011123. doi: 10.1128/aac.00111-23. Online ahead of print.ABSTRACTMultiresistance plasmids belonging to the IncI incompatibility group have become one of the most pervasive plasmid types in extended-spectrum beta-lactamase-producing Escherichia coli of animal origin. The extent of the burden imposed on the bacterial cell by these plasmids seems to modulate the emergence of "epidemic" plasmids. However, in vivo data in the natural environment of the strains are scarce. Here, we investigated the cost of a blaCTX-M-1-IncI1 epidemic plasmid in a commensal E. coli animal strain, UB12-RC...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Margaux Allain Anne Claire Mah érault Benoit Gachet Caroline Martinez B énédicte Condamine M élanie Magnan Isabelle Kempf Erick Denamur Luce Landraud Source Type: research
Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing < em > Escherichia coli < /em >
Antimicrob Agents Chemother. 2023 Sep 13:e0051023. doi: 10.1128/aac.00510-23. Online ahead of print.ABSTRACTCefmetazole is active against extended-spectrum β-lactamase-producing Escherichia coli (ESBLEC) and is a potential candidate for carbapenem-sparing therapy. This multicenter, observational study included patients hospitalized for invasive urinary tract infection due to ESBLEC between March 2020 and November 2021 at 10 facilities in Japan, for whom either cefmetazole or meropenem was initiated as a definitive therapy within 96 h of culture collection and continued for at least 3 d. Outcomes included clinical and micr...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Kayoko Hayakawa Yasufumi Matsumura Kohei Uemura Shinya Tsuzuki Aki Sakurai Ryutaro Tanizaki Koh Shinohara Takehiro Hashimoto Ryota Hase Takashi Matono Hideaki Kato Momoko Mawatari Hiroshi Hara Yukihiro Hamada Sho Saito Norio Ohmagari Yohei Doi Source Type: research
Dissemination of IncI plasmid encoding < em > bla < /em > < sub > CTX-M-1 < /sub > is not hampered by its fitness cost in the pig's gut
Antimicrob Agents Chemother. 2023 Sep 13:e0011123. doi: 10.1128/aac.00111-23. Online ahead of print.ABSTRACTMultiresistance plasmids belonging to the IncI incompatibility group have become one of the most pervasive plasmid types in extended-spectrum beta-lactamase-producing Escherichia coli of animal origin. The extent of the burden imposed on the bacterial cell by these plasmids seems to modulate the emergence of "epidemic" plasmids. However, in vivo data in the natural environment of the strains are scarce. Here, we investigated the cost of a blaCTX-M-1-IncI1 epidemic plasmid in a commensal E. coli animal strain, UB12-RC...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Margaux Allain Anne Claire Mah érault Benoit Gachet Caroline Martinez B énédicte Condamine M élanie Magnan Isabelle Kempf Erick Denamur Luce Landraud Source Type: research
Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing < em > Escherichia coli < /em >
Antimicrob Agents Chemother. 2023 Sep 13:e0051023. doi: 10.1128/aac.00510-23. Online ahead of print.ABSTRACTCefmetazole is active against extended-spectrum β-lactamase-producing Escherichia coli (ESBLEC) and is a potential candidate for carbapenem-sparing therapy. This multicenter, observational study included patients hospitalized for invasive urinary tract infection due to ESBLEC between March 2020 and November 2021 at 10 facilities in Japan, for whom either cefmetazole or meropenem was initiated as a definitive therapy within 96 h of culture collection and continued for at least 3 d. Outcomes included clinical and micr...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Kayoko Hayakawa Yasufumi Matsumura Kohei Uemura Shinya Tsuzuki Aki Sakurai Ryutaro Tanizaki Koh Shinohara Takehiro Hashimoto Ryota Hase Takashi Matono Hideaki Kato Momoko Mawatari Hiroshi Hara Yukihiro Hamada Sho Saito Norio Ohmagari Yohei Doi Source Type: research
Dissemination of IncI plasmid encoding < em > bla < /em > < sub > CTX-M-1 < /sub > is not hampered by its fitness cost in the pig's gut
Antimicrob Agents Chemother. 2023 Sep 13:e0011123. doi: 10.1128/aac.00111-23. Online ahead of print.ABSTRACTMultiresistance plasmids belonging to the IncI incompatibility group have become one of the most pervasive plasmid types in extended-spectrum beta-lactamase-producing Escherichia coli of animal origin. The extent of the burden imposed on the bacterial cell by these plasmids seems to modulate the emergence of "epidemic" plasmids. However, in vivo data in the natural environment of the strains are scarce. Here, we investigated the cost of a blaCTX-M-1-IncI1 epidemic plasmid in a commensal E. coli animal strain, UB12-RC...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Margaux Allain Anne Claire Mah érault Benoit Gachet Caroline Martinez B énédicte Condamine M élanie Magnan Isabelle Kempf Erick Denamur Luce Landraud Source Type: research
Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing < em > Escherichia coli < /em >
Antimicrob Agents Chemother. 2023 Sep 13:e0051023. doi: 10.1128/aac.00510-23. Online ahead of print.ABSTRACTCefmetazole is active against extended-spectrum β-lactamase-producing Escherichia coli (ESBLEC) and is a potential candidate for carbapenem-sparing therapy. This multicenter, observational study included patients hospitalized for invasive urinary tract infection due to ESBLEC between March 2020 and November 2021 at 10 facilities in Japan, for whom either cefmetazole or meropenem was initiated as a definitive therapy within 96 h of culture collection and continued for at least 3 d. Outcomes included clinical and micr...
Source: Antimicrobial Agents and Chemotherapy - September 13, 2023 Category: Microbiology Authors: Kayoko Hayakawa Yasufumi Matsumura Kohei Uemura Shinya Tsuzuki Aki Sakurai Ryutaro Tanizaki Koh Shinohara Takehiro Hashimoto Ryota Hase Takashi Matono Hideaki Kato Momoko Mawatari Hiroshi Hara Yukihiro Hamada Sho Saito Norio Ohmagari Yohei Doi Source Type: research
Oral administration of a 2-aminopyrimidine robenidine analogue (NCL195) significantly reduces < em > Staphylococcus aureus < /em > infection and reduces < em > Escherichia coli < /em > infection in combination with sub-inhibitory colistin concentrations in a bioluminescent mouse model
In this study, we examined the efficacy of oral treatment with NCL195 (± low-dose colistin) in comparison to oral moxifloxacin in bioluminescent Staphylococcus aureus and Escherichia coli peritonitis-sepsis models. Four oral doses of 50 mg/kg NCL195, commencing immediately post-infection, were administered at 4 h intervals in the S. aureus peritonitis-sepsis model. We used a combination of four oral doses of 50 mg/kg NCL195 and four intraperitoneal doses of colistin at 0.125 mg/kg, 0.25 mg/kg, or 0.5 mg/kg in the E. coli peritonitis-sepsis model. Subsequently, the dose rates of four intraperitoneal doses of colistin were ...
Source: Antimicrobial Agents and Chemotherapy - September 11, 2023 Category: Microbiology Authors: Hang Thi Nguyen Henrietta Venter Lucy Woolford Kelly A Young Adam McCluskey Sanjay Garg Sylvia S Sapula Stephen W Page Abiodun David Ogunniyi Darren J Trott Source Type: research
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in < em > Escherichia coli < /em >
Antimicrob Agents Chemother. 2023 Sep 5:e0054723. doi: 10.1128/aac.00547-23. Online ahead of print.ABSTRACTThe impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Escherichia coli, alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a similar spectrum of activity compared to the intravenous carbapenems and displayed lower MIC values than ceftibuten-avibactam against E. coli producing extended-spectrum β-lactamases or AmpC enzymes. Combined with taniborbactam...
Source: Antimicrobial Agents and Chemotherapy - September 5, 2023 Category: Microbiology Authors: Christophe Le Terrier Patrice Nordmann Maxime Bouvier Laurent Poirel Source Type: research
